Patent classifications
C12R2001/545
NOVEL DAPTOMYCIN-PRODUCING STREPTOMYCES STRAIN AND USE THEREOF
The present invention provides a novel daptomycin-producing Streptomyces strain and use thereof, the strain is a subspecies of streptomyces griseus, named Streptomyces griseus L340, and the preservation number is CGMCC17921. The genetic character and fermentation unit of the strain provided by the present invention are relatively stable, the culture and fermentation conditions are suitable for industrial production of daptomycin, and the interference of pigment in later separation and purification is eliminated. The secondary metabolite daptomycin is obtained through fermentation of the Streptomyces provided by the present invention, which has the advantages of no interference of pigment accumulation, cleaner metabolic spectrum and thus is obviously superior in later separation and purification.
Genetically modified host organism for expressing an anthracyclinone analogue, method associated therewith, and synthetic nucleic acids
Disclosed is a genetically modified host organism for expressing an anthracyclinone analogue. The genetically modified host organism comprises (i) synthetic nucleic acids; (ii) a biosynthetic pathway encoded by the synthetic nucleic acids, the (ii) biosynthetic pathway comprising a ketosynthase alpha, a ketosynthase beta/chain-length factor, an acyl carrier protein, a 3-oxoacyl-ACP synthase, a propionyl-CoA acyltransferase, a 9-ketoreductase, an aromatase/cyclase, and a second/third-ring cyclase; and (iii) a promoter positioned upstream of and operatively associated with the (ii) biosynthetic pathway. A method and corresponding synthetic nucleic acids are also disclosed.
Daptomycin-producing Streptomyces strain and use thereof
The present invention provides a novel daptomycin-producing Streptomyces strain and use thereof, the strain is a subspecies of streptomyces griseus, named Streptomyces griseus L340, and the preservation number is CGMCC17921. The genetic character and fermentation unit of the strain provided by the present invention are relatively stable, the culture and fermentation conditions are suitable for industrial production of daptomycin, and the interference of pigment in later separation and purification is eliminated. The secondary metabolite daptomycin is obtained through fermentation of the Streptomyces provided by the present invention, which has the advantages of no interference of pigment accumulation, cleaner metabolic spectrum and thus is obviously superior in later separation and purification.
GENETICALLY MODIFIED HOST ORGANISM FOR EXPRESSING AN ANTHRACYCLINONE ANALOGUE, METHOD ASSOCIATED THEREWITH, AND SYNTHETIC NUCLEIC ACIDS
Disclosed is a genetically modified host organism for expressing an anthracyclinone analogue. The genetically modified host organism comprises (i) synthetic nucleic acids; (ii) a biosynthetic pathway encoded by the synthetic nucleic acids, the (ii) biosynthetic pathway comprising a ketosynthase alpha, a ketosynthase beta/chain-length factor, an acyl carrier protein, a 3-oxoacyl-ACP synthase, a propionyl-CoA acyltransferase, a 9-ketoreductase, an aromatase/cyclase, and a second/third-ring cyclase; and (iii) a promoter positioned upstream of and operatively associated with the (ii) biosynthetic pathway. A method and corresponding synthetic nucleic acids are also disclosed.